Cutaneous leishmaniasis

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
Tuesday, April 2, 2024
Health, Defense, Infectious Diseases, Pharmaceutical, Contracts, Biotechnology, Ulcer, Paromomycin, Patient, NTD, IND, Metronidazole, Francisella tularensis, Infection, OTCQX, Therapy, Priority review, USD, Risk, Systemic, NIH, Anthrax, Arrangement, World Health Organization, Investigational New Drug, Calendar, Scar, Neglected tropical diseases, Tablet, Public, Research, News, PRV, Acquisition, TSX, Drug development, Population health, Cutaneous leishmaniasis, Canada Business Corporations Act, FDA, Transaction, Government, Growth, Entrepreneurship, Skin infection, Share, Procurement, WHO, Pharmaceutical industry

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

International Photodynamic Association: Global Experts Gather in Finland to Discuss Advances in Photomedicine – a Leading Alternative to Antibiotics in the Battle Against AMR

Retrieved on: 
Thursday, July 6, 2023
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, Dentistry, Infection, Gold medal, Harvard–MIT Program in Health Sciences and Technology, University, PIT, PD, Life, World Congress, Sleep hygiene, PDT, PDD, Attention, AMR, Cutaneous leishmaniasis, Fungus, Doctor of Philosophy, Harvard Medical School, University of Coimbra, IPA, Congress, Hospital, Sinusitis, Patient, Outline of health sciences, Diagnosis, Fungal infection, Photodynamic therapy, Bacteria, HMS, Virus, Skin, Vaccine, Pharmaceutical industry, Dermatology, Chemistry

APDT has not only proven to be effective against all types of pathogens but does not generate resistance or serious adverse effects unlike antibiotics.

Key Points: 
  • APDT has not only proven to be effective against all types of pathogens but does not generate resistance or serious adverse effects unlike antibiotics.
  • There are a growing number of applications for aPDT that are being developed in leading research centres around the world.
  • It is gratifying to see the quality of research and commercial applications being showcased at this World Congress.
  • The Biennial International Photodynamic Association World Congress aims to bring together researchers and clinicians in all fields of Photodynamic Therapy (PDT) and Photodiagnosis (PDD) since 1986.

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

Retrieved on: 
Friday, June 23, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Taste, Pharming, Social stigma, Defense Threat Reduction Agency, Patent, Patient, Government, R, Ulcer, International Accounting Standards Board, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Research, Net, SEDAR, TSX, FDA, Skin, Delays, Cutaneous leishmaniasis, United States Patent and Trademark Office, Scar, Parasitism, Metronidazole, DOD, Non-governmental organization, Fast track (FDA), The Last of Us Part I, Therapy, Accounting, Partnership, PRV, Drug development, Bank statement, USAFA, NDA, United States Air Force Academy, Sale, State, Indian stock exchange, Anthrax, Pharmaceutical industry, Cryptocurrency, Tularemia, IND

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.
  • In May 2023, Appili executed the initial contract with USAFA (the “USAFA Cooperative Agreement”) for the previously announced funding of the ATI-1701 program.
  • Appili has submitted its first invoice for such costs and anticipates receiving payment by the end of June 2023.
  • The Company has included a going concern note in its financial statements for the fiscal year ended March 31, 2023.

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Retrieved on: 
Tuesday, February 14, 2023
Defense, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Contracts, Bank statement, New Drug Application, Toxicology, NDA, Mouse, Taste, Tularemia, Animal, The Last of Us Part I, Parasitism, Paromomycin, Safety, SEDAR, International Accounting Standards Board, U.S. Department of Defense Strategy for Operating in Cyberspace, Metronidazole, Air force, OTCQB, Indian stock exchange, Infection, Food and Drug Administration, Vaccination, Food, Survival, FDA, MD, Government, PDUFA, Patient, State, United States Department of Defense, Skin, Sale, Research, Therapy, Funding, Anthrax, TSX, Drug development, Pharming, Disease, Cutaneous leishmaniasis, IND, Pharmaceutical industry, Vaccine, Cryptocurrency, PRV

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.
  • We are working diligently with our partner, Saptalis, and the FDA on receiving NDA approval and preparing for market launch.
  • There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets.
  • As of February 13, 2023, the Company had 121,226,120­ issued and outstanding Common Shares, 8,081,772 ­stock options, and 51,317,879­­ warrants outstanding.

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

Retrieved on: 
Tuesday, August 2, 2022
Research, Other Defense, Infectious Diseases, Biotechnology, General Health, Pharmaceutical, Health, Science, Defense, Other Science, TSX, Infection, Social stigma, Leishmaniasis, Defense, Universidad, CL, Cutaneous leishmaniasis, Woman, Research, Intention, Scar, Therapy, Ulcer, Safety, News, Hospital, United States Army Medical Materiel Agency, Drug development, Company, Patient, Skin infection, Death, Growth, Leishmania, U.S. Department of Defense Strategy for Operating in Cyberspace, OTCQX, Pharmaceutical industry, M.D

Presentation details for Appili are as follows:

Key Points: 
  • Presentation details for Appili are as follows:
    Location: Programa de Estudio y Control de Enfermedades Tropicales of the Universidad de Antioquia, Colombia
    Appili management will also be conducting in-person meetings throughout the conference.
  • To request a meeting, please register for the conference here .
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

Retrieved on: 
Wednesday, June 29, 2022
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, Atlas Shrugged: Part I, SEDAR, Priority review, Patient, OTCQX, Defense Threat Reduction Agency, Research, Cutaneous leishmaniasis, TSX, Accounting, R, Death, Infection, Growth, Company, U.S. Department of Defense Strategy for Operating in Cyberspace, International Accounting Standards Board, Net, DTRA, Defense, Bacteria, Partnership, LLC, IFRS, Mission statement, Investment, Indian stock exchange, Francisella tularensis, Skin, Drug development, Government, Tularemia, News, MD, Intention, Therapy, Pharmaceutical industry, Security (finance)

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Companys strategy for fiscal 2023.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Companys strategy for fiscal 2023.
  • At March 31, 2022, the Company had cash and short-term investments of $6.7 million compared to $16.1 million at March 31, 2021.
  • As of June 23, 2022, the Company had 121,266,120 issued and outstanding Common Shares, 9,276,490 stock options and 49,817,879 warrants outstanding.
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Wednesday, April 27, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Drug development, Cutaneous leishmaniasis, Infection, Investment Industry Regulatory Organization of Canada, OTCQX, Corporate development, Conference, Death, Company, Canadian Investor Protection Fund, IIROC, TSX, Therapy, Pharmaceutical industry

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on May 2 and 3, 2022.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on May 2 and 3, 2022.
  • Presentation details are as follows:
    Appili management will also be conducting one-to-one meetings throughout the conference.
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
  • About Bloom Burton & Co.:
    Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

Retrieved on: 
Wednesday, April 13, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Drug development, News, CEO, Cutaneous leishmaniasis, Government, Disability, Social stigma, Woman, Index, US Foods, Risk, Ulcer, Intention, Non-governmental organization, Food, Infection, PRV, OTCQX, Program, Patient, Review, Francisella tularensis, Death, Company, Skin, Therapy, V6 PRV engine, TSX, Safety, Scar, Partnership, FDA, Disease, Hospital, Leishmaniasis, Pharmaceutical industry

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases, today announced the addition of ATI-1801, a clinical stage topical paromomycin product to treat cutaneous leishmaniasis, to its development pipeline.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases, today announced the addition of ATI-1801, a clinical stage topical paromomycin product to treat cutaneous leishmaniasis, to its development pipeline.
  • Appili holds the full clinical dossier for ATI-1801, including the results of a randomized, double-blind, vehicle-controlled Phase 3 study which evaluated the safety and efficacy of ATI-1801 for the treatment of cutaneous leishmaniasis in Tunisia.
  • The PRV program was developed to incentivize drug development in US government priority areas including medical countermeasures and tropical diseases such as leishmaniasis.
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Retrieved on: 
Tuesday, September 29, 2020
Infectious diseases, Medical specialties, Leishmaniasis, Tropical diseases, Ajinomoto, Cutaneous leishmaniasis

"We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.

Key Points: 
  • "We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.
  • "We are very pleased to be partnering with Ajinomoto Bio-Pharma Services for the supply of promising new therapeutic for the treatment of cutaneous leishmaniasis," said Dr Byron Arana, Head of Cutaneous Leishmaniasis Programme at DNDi.
  • "With this partnership, we continue our goal to develop and provide safe and effective cutaneous leishmaniasis therapeutics."
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs.

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Retrieved on: 
Tuesday, September 29, 2020
Infectious diseases, Medical specialties, Leishmaniasis, Tropical diseases, Ajinomoto, Cutaneous leishmaniasis

"We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.

Key Points: 
  • "We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.
  • "We are very pleased to be partnering with Ajinomoto Bio-Pharma Services for the supply of promising new therapeutic for the treatment of cutaneous leishmaniasis," said Dr Byron Arana, Head of Cutaneous Leishmaniasis Programme at DNDi.
  • "With this partnership, we continue our goal to develop and provide safe and effective cutaneous leishmaniasis therapeutics."
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs.